Literature DB >> 23974699

Chronological effects of rifampicin discontinuation on cytochrome P450 activity in healthy Japanese volunteers, using the cocktail method.

N Inui1, T Akamatsu, S Uchida, S Tanaka, N Namiki, M Karayama, K Chida, H Watanabe.   

Abstract

Cytochrome P450 (CYP) 1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A are major factors involved in the metabolism of clinically prescribed drugs. Because the time course after drug treatment discontinuation has received little attention, we aimed to clarify the chronological changes of rifampicin-induced CYP enzyme activities after rifampicin discontinuation. Thirteen volunteers took 450 mg of rifampicin once daily, and the cocktail method, which uses caffeine, losartan, omeprazole, dextromethorphan, and midazolam as CYP-specific probes, was repeatedly used for the evaluation of CYP levels. Concentrations of probes and metabolites were determined by liquid chromatography-tandem mass spectrometry. Seven-day rifampicin administration increased CYP2C19 and CYP3A enzyme activities. The induced CYP2C19 and CYP3A activities remained elevated at 4 days after rifampicin discontinuation and returned to baseline levels 8 days after rifampicin discontinuation. CYP1A2 and CYP2D6 enzyme activities showed no significant changes, and CYP2C9 enzyme activity was increased with rifampicin administration, with a tendency toward statistical significance. Drug interactions can occur even after rifampicin discontinuation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23974699     DOI: 10.1038/clpt.2013.167

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  8 in total

1.  Problems in anticoagulation of a patient with antibiotic treatment for endocarditis: interaction of rifampicin and vitamin K antagonists.

Authors:  Lars Mizera; Tobias Geisler; Klaus Mörike; Meinrad Gawaz; Martin Steeg
Journal:  BMJ Case Rep       Date:  2018-02-12

2.  Dicloxacillin induces CYP2C19, CYP2C9 and CYP3A4 in vivo and in vitro.

Authors:  Tore Bjerregaard Stage; Magnus Graff; Susan Wong; Louise Ladebo Rasmussen; Flemming Nielsen; Anton Pottegård; Kim Brøsen; Deanna L Kroetz; S Cyrus Khojasteh; Per Damkier
Journal:  Br J Clin Pharmacol       Date:  2018-01-10       Impact factor: 4.335

3.  Effects of Cytochrome P450 Inhibition and Induction on the Phenotyping Metrics of the Basel Cocktail: A Randomized Crossover Study.

Authors:  Adrian Derungs; Massimiliano Donzelli; Benjamin Berger; Christoph Noppen; Stephan Krähenbühl; Manuel Haschke
Journal:  Clin Pharmacokinet       Date:  2016-01       Impact factor: 6.447

4.  Influence of serum inflammatory cytokines on cytochrome P450 drug metabolising activity during breast cancer chemotherapy: a patient feasibility study.

Authors:  Rebekah L I Crake; Matthew R Strother; Elisabeth Phillips; Matthew P Doogue; Mei Zhang; Chris M A Frampton; Bridget A Robinson; Margaret J Currie
Journal:  Sci Rep       Date:  2021-03-11       Impact factor: 4.379

5.  Effect of rifampicin and clarithromycin on the CYP3A activity in patients with Mycobacterium avium complex.

Authors:  Norimichi Akiyama; Naoki Inui; Kazutaka Mori; Yutaro Nakamura; Hiroshi Hayakawa; Shimako Tanaka; Shinya Uchida; Noriyuki Namiki; Hiroshi Watanabe; Takafumi Suda
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

6.  Geneva cocktail for cytochrome p450 and P-glycoprotein activity assessment using dried blood spots.

Authors:  M Bosilkovska; C F Samer; J Déglon; M Rebsamen; C Staub; P Dayer; B Walder; J A Desmeules; Y Daali
Journal:  Clin Pharmacol Ther       Date:  2014-04-10       Impact factor: 6.875

7.  Interaction between Fexofenadine and CYP Phenotyping Probe Drugs in Geneva Cocktail.

Authors:  Marija Bosilkovska; Gaelle Magliocco; Jules Desmeules; Caroline Samer; Youssef Daali
Journal:  J Pers Med       Date:  2019-10-02

8.  Anemarsaponin BII inhibits the activity of CYP3A4, 2D6, and 2E1 with human liver microsomes.

Authors:  Mingwei Wang; Wei Jiang; Juan Zhou; Xiujuan Xue; Changlong Yin
Journal:  Pharm Biol       Date:  2020-12       Impact factor: 3.503

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.